Purchase Order N0025918P0597
Award Date 8/29/18
Potential Completion Date 7/1/21
Potential Value $190K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Concord, CA 94520, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Health Agency has awarded Cerus Corporation, a for-profit manufacturer of biomedical products, a $87,166.08 firm fixed price purchase order contract to provide the INTERCEPT Blood System for Platelets. This pathogen reduction technology uses riboflavin and UV light to inactivate viruses, bacteria, protozoa, and contaminating white blood cells in platelet components. The contract, which does not have a set-aside designation, will run through June 18, 2024. Cerus has received over 20...
- The Defense Health Agency awarded a $104,256 firm fixed-price purchase order to Cerus Corporation on September 30, 2019, for INTERCEPT Platelet Small Volume Sets, with performance through September 3, 2024. The contract was awarded without a set-aside designation to Cerus Corporation, a Concord, California-based biomedical products manufacturer specializing in blood safety technologies. Cerus's INTERCEPT Blood System uses riboflavin and ultraviolet light technology to inactivate pathogens in...
- This firm-fixed-price purchase order was awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company, for the provision of INTERCEPT Platelet Processing Sets. Valued at $137,664.00, the contract does not have a set-aside designation. Cerus has received over 20 previous prime federal contract awards from agencies including the DoD, VA, and HHS to provide pathogen reduction technologies, equipment, and associated services to support military and veterans' medical...
- The Defense Health Agency awarded a $199,584 firm fixed-price purchase order to Cerus Corporation on January 5, 2024, for the procurement of Intercept Platelet Sets (PN INT2140B). The contract, which carries an ultimate completion date of September 30, 2028, will be performed at Cerus Corporation's facility in Concord, California. This award represents a continuation of the Defense Health Agency's established relationship with Cerus Corporation for blood safety technologies, specifically the...
- The Defense Health Agency awarded a firm fixed-price purchase order to Cerus Corporation for $367.1K on October 1, 2025, with an ultimate completion date of September 30, 2030. The contract covers Cerus Intercept Platelet Processing Sets, specialized medical equipment used in blood pathogen reduction treatment. Cerus Corporation, a biomedical products manufacturer headquartered in Concord, California, specializes in blood safety technologies and the proprietary INTERCEPT Blood System, which uses...
- The Defense Health Agency (DOD) awarded a $367,504.80 firm fixed price purchase order to Cerus Corporation to provide INTERCEPT Platelet Processing and Service Maintenance for the Walter Reed National Military Center in Bethesda, Maryland from January 13, 2022 through January 31, 2027. Cerus Corporation will supply its INTERCEPT Blood System for platelets, which utilizes ultraviolet light and riboflavin to inactivate pathogens in platelet components during the collection and storage process,...
- This is a firm fixed-price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract, valued at $146,200.00, is for the procurement of INTERCEPT Blood System processing sets for dual storage. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components such as platelets and plasma, enhancing blood safety. Cerus has a history of supplying its...
- The Defense Health Agency awarded a Firm Fixed Price, $186,048.00 purchase order contract to Cerus Corporation, a biomedical products manufacturer, for the drop shipment of medical supplies. The contract is sole source and not set aside. The supplies include the INTERCEPT Blood System technology, which uses riboflavin and UV light to inactivate pathogens in blood platelets and plasma. Cerus has received over 20 federal contract awards since 2002 from agencies such as the Department of Defense,...
- The Defense Health Agency (DHA) awarded a $214,560 firm fixed-price purchase order to Cerus Corporation on February 21, 2025, for drop shipment delivery of platelet processing sets under the INTERCEPT Platelet system. The contract, which carries no set-aside designation, is scheduled for completion by February 23, 2028, with performance taking place in Portsmouth, Virginia. Cerus Corporation, a biomedical products manufacturer headquartered in Concord, California, specializes in blood safety...
- Cerus Corporation received a firm fixed-price purchase order from the Defense Health Agency (DHA) on August 27, 2021, for INTERCEPT Platelet Set-Small units (Part No. INT2130B), with a ceiling value of $218,371.20 and an ultimate completion date of October 1, 2024. The contract was awarded without a set-aside designation and will be performed in Concord, California, where Cerus maintains its headquarters. Cerus Corporation specializes in blood safety technologies and pathogen reduction...